OBJECTIVE: The objective of this selective EBM review is to determine whether or not botulinum toxin A is an effective treatment for children who have lower limb spasticity from cerebral palsy. STUDY DESIGN: The study by Carraro et al was a randomized double-blind clinical trial done in 2015.6The study done by Kim et al was a randomized, double-blind controlled clinical trial done in 2010.7 The study by Py et al was a clinical trial done in 2005-2006.8 DATA SOURCES: Data sources obtained for this review were articles published in peerreviewed journals found using PubMed Database. OUTCOMES MEASURED: The outcome measured the effectiveness of Botox and Botox verse Xeomin and Neuronox, as well as the improvement of Gross Motor function with the...
Cerebral palsy (CP) affects around every one in 500 children born. It isn’t a particular illness or ...
Contains fulltext : 50246.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...
This study evaluated the efficacy and safety of three doses of botulinum toxin A (BTX-A; Dysport®) i...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not botulinum toxin...
INTRODUCTION: Cerebral palsy is the most common cause of physical disability in children. Spasticity...
Introduction: Cerebral palsy (CP) is a group of disorders that affect muscle movement, tone and coor...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
Background: Spasticity is common in cerebral palsy and can result in pain and diminished health-rela...
CP is the most common cause of chronic disability in childhood occurring in 2-2.5/1000 births. It is...
The objective of this study was to assess the efficacy of botulinum toxin for upper limb spasticity ...
Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-A) in t...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
The aim of this article was to present a review of the research literature on the outcome of botulin...
Background & objectives: Botulinum toxin is considered as an effective treatment for spasticity in c...
Item does not contain fulltextAIM: To assess treatment effects of botulinum toxin type A (BoNT-A) on...
Cerebral palsy (CP) affects around every one in 500 children born. It isn’t a particular illness or ...
Contains fulltext : 50246.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...
This study evaluated the efficacy and safety of three doses of botulinum toxin A (BTX-A; Dysport®) i...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not botulinum toxin...
INTRODUCTION: Cerebral palsy is the most common cause of physical disability in children. Spasticity...
Introduction: Cerebral palsy (CP) is a group of disorders that affect muscle movement, tone and coor...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
Background: Spasticity is common in cerebral palsy and can result in pain and diminished health-rela...
CP is the most common cause of chronic disability in childhood occurring in 2-2.5/1000 births. It is...
The objective of this study was to assess the efficacy of botulinum toxin for upper limb spasticity ...
Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-A) in t...
BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination w...
The aim of this article was to present a review of the research literature on the outcome of botulin...
Background & objectives: Botulinum toxin is considered as an effective treatment for spasticity in c...
Item does not contain fulltextAIM: To assess treatment effects of botulinum toxin type A (BoNT-A) on...
Cerebral palsy (CP) affects around every one in 500 children born. It isn’t a particular illness or ...
Contains fulltext : 50246.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...
This study evaluated the efficacy and safety of three doses of botulinum toxin A (BTX-A; Dysport®) i...